You are currently viewing a new version of our website. To view the old version click .
Polymers
  • Review
  • Open Access

2 August 2022

Application of Fibrin Associated with Photobiomodulation as a Promising Strategy to Improve Regeneration in Tissue Engineering: A Systematic Review

,
,
,
,
,
,
,
,
and
1
UNIMAR Beneficent Hospital (HBU), University of Marilia (UNIMAR), Marilia 17525-160, Brazil
2
Department of Biological Sciences, Bauru School of Dentistry (FOB/USP), University of São Paulo, Bauru 17012-901, Brazil
3
Postgraduate Program in Structural and Functional Interactions in Rehabilitation, Postgraduate Department, University of Marilia (UNIMAR), Marilia 17525-902, Brazil
4
Teaching and Research Coordination of the Medical School, University Center of Adamantina (UniFAI), Adamantina 17800-000, Brazil
This article belongs to the Special Issue Polymers for Medical and Dental Applications

Abstract

Fibrin, derived from proteins involved in blood clotting (fibrinogen and thrombin), is a biopolymer with different applications in the health area since it has hemostasis, biocompatible and three-dimensional physical structure properties, and can be used as scaffolds in tissue regeneration or drug delivery system for cells and/or growth factors. Fibrin alone or together with other biomaterials, has been indicated for use as a biological support to promote the regeneration of stem cells, bone, peripheral nerves, and other injured tissues. In its diversity of forms of application and constitution, there are platelet-rich fibrin (PRF), Leukocyte- and platelet-rich fibrin (L-PRF), fibrin glue or fibrin sealant, and hydrogels. In order to increase fibrin properties, adjuvant therapies can be combined to favor tissue repair, such as photobiomodulation (PBM), by low-level laser therapy (LLLT) or LEDs (Light Emitting Diode). Therefore, this systematic review aimed to evaluate the relationship between PBM and the use of fibrin compounds, referring to the results of previous studies published in PubMed/MEDLINE, Scopus and Web of Science databases. The descriptors “fibrin AND low-level laser therapy” and “fibrin AND photobiomodulation” were used, without restriction on publication time. The bibliographic search found 44 articles in PubMed/MEDLINE, of which 26 were excluded due to duplicity or being outside the eligibility criteria. We also found 40 articles in Web of Science and selected 1 article, 152 articles in Scopus and no article selected, totaling 19 articles for qualitative analysis. The fibrin type most used in combination with PBM was fibrin sealant, mainly heterologous, followed by PRF or L-PRF. In PBM, the gallium-aluminum-arsenide (GaAlAs) laser prevailed, with a wavelength of 830 nm, followed by 810 nm. Among the preclinical studies, the most researched association of fibrin and PBM was the use of fibrin sealants in bone or nerve injuries; in clinical studies, the association of PBM with medication-related treatments osteonecrosis of the jaw (MRONJ). Therefore, there is scientific evidence of the contribution of PBM on fibrin composites, constituting a supporting therapy that acts by stimulating cell activity, angiogenesis, osteoblast activation, axonal growth, anti-inflammatory and anti-edema action, increased collagen synthesis and its maturation, as well as biomolecules.

1. Introduction

The word fibrin, in etymology, derives from the Latin ‘fibre’ (fiber) and –in (chemical substance). It can be defined as a protein formed in blood plasma from the action of thrombin on fibrinogen, being the main component of blood clots (that is, fibrin aggregating produces clots). Wound healing depends entirely on the initial mechanisms of tissue homeostasis. When an injury occurs, the first tissue to respond is blood, as bleeding is a potentially serious risk to the body. There is a cascade of molecular and cellular reactions that lead to the sealing of the vascular lesion with an aggregate of platelets, which stop the hemorrhage by forming a tampon in the injured tissue, triggering the next steps of tissue regeneration. Stable blood clot, containing cross-linked and polymerized fibrin, is essential to prevent bleeding and lead to wound repair after vascular injury [,].
Fibrin is a viscoelastic polymer and its mechanical and structural properties as a fibrin scaffold determine its effectiveness in hemostasis and in the development and outcome of thrombotic complications. Fibrin polymerization comprises a series of consecutive reactions, each affecting the final structure of the 3D porous network. Structural features in the fibrin molecule determine the physical properties of clots, and it is important for the blood clot to support arterial flow, clot contraction by platelets, and other dynamic forces [,].
The three-dimensional structure of fibrin allows for a series of cellular interactions and provides a temporary matrix in which cells can proliferate, organize, and perform their functions, especially at injured or inflamed sites. Thus, fibrin has been used with the aim of accelerating healing and regeneration in several surgical procedures, especially in medicine in the areas of orthopedics [,], neurology [,,], and plastic surgery [,], as well as in dentistry in the areas of periodontics [,], implantology [,], and oral and maxillofacial surgery [,].
One of the ways to use fibrin in tissue regeneration is platelet-rich fibrin (PRF) which, unlike platelet-rich plasma (PRP), PRF has a high concentration of fibrin and white blood cells, not platelets. PRP and PRF have the same ability to accelerate the healing of soft and hard tissues by increasing the concentration of growth factors, but PRF acts to release growth factors over a longer period, providing longer lasting benefits, as well as stimulating a faster healing process than PRP []. PRF increases the concentration of these factors, among which we can exemplify the platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), factors which help to accelerate neovascularization and cell differentiation [,].
Studies also evaluate “fibrin glues” that can be called fibrin adhesive, fibrin sealant or fibrin biopolymer in tissue regeneration [,,,]. Human fibrin glue is manufactured using two components, one of which is a concentrate of clotting proteins (fibrinogen, fibronectin and Factor XIII) and the other is thrombin, both lyophilized. The first component is reconstituted with an aprotinin solution that inhibits tissue fibrinolysis. Thrombin is mixed with calcium chloride, thus being a grouping of substances participating in hemostasis and wound repair, giving the product properties such as hemostatic action, sealant and biological stimulation, which favor the formation of new tissue matrix [,]. In Brazil, a group of researchers from the Center for the Study of Venoms and Venomous Animals (CEVAP/UNESP Botucatu) developed and has been using in several studies, a fibrin sealant without the presence of derivatives from human blood, being totally heterologous, which has components derived from snake venom and fibrinogen from buffalo blood. This sealant, due to its diversity of use, is currently called fibrin biopolymer [,].
However, in view of the search for a rapid morphological and functional recovery of the injured tissues, more than one type of therapy can be combined (in this case, a set of therapies complementary to the treatment). One of them is the low-level laser (LLLT), with tissue stimulation properties through red or infrared light with the ability to modulate the repair process, reducing pain, increasing tissue vascularization, promoting an increase in the production of mitochondrial ATP, and a series of biostimulatory effects, which led to the current name of photobiomodulation (PBM) therapy [,].
The combined use of fibrin glue with photobiomodulation has shown promising results in the repair of peripheral nerve injuries, being effective in the neurorrhaphy procedure, as well as providing a better quality of axonal regeneration to the interior of the distal stump []. In addition, this associated form of therapeutic use has demonstrated the ability to assist in the repair process of bone defects, stimulating angiogenesis and osteoblast proliferation, contributing to the formation of new bone in shorter postoperative periods and in greater volume [].
However, there are still gaps in explaining the mechanisms of PBM therapy and its effects in combination therapies with fibrin. Therefore, this systematic review was designed from the PICO strategy (P: problem; I: intervention; C: control; O: outcome) [,], in order to analyze the relationship between PBM therapy and the use of fibrin compounds, such as PRF and fibrin sealants.

2. Materials and Methods

This systematic review was developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist, as well as other similar research [,,]. For this, PubMed/MEDLINE, Scopus (Elsevier) and Web of Science databases were searched, with a specific search period (1 January 2002–30 April 2022), using the keywords: “fibrin AND low-level laser therapy” and “fibrin AND photobiomodulation”.
With the crossing of keywords, a detailed analysis of the results was carried out, being important in the selection the title and the abstract. From there, the manuscripts were separated into included and excluded according to the eligibility criteria. The authors carried out this process impartially and independently.
-
Eligibility Criteria:
The inclusion criteria were:
  • Therapeutic use of fibrin and PBM therapy as complementary therapy;
  • Studies in humans;
  • Studies in animals;
  • In vivo studies;
  • Case reports;
  • Publications only in English and that allowed full access to the text;
  • Each article included must present data on the PBM protocol.
-
The exclusion criteria were:
  • Articles that were duplicated;
  • When the title had no connection to the objective;
  • Did not use fibrin;
  • Did not use photobiomodulation;
  • Used high power laser;
  • Other languages (except English);
  • When access to the full text was not obtained;
  • Incomplete data on the type of fibrin used.
  • Letters to the editor;
  • Review papers;
  • Commentaries;
  • Unpublished abstracts;
  • Dissertations or theses from repositories
Initially, the manuscripts with the title and abstract connected to the topic of the search were verified, with the terms: fibrin and PBM therapy, and then we evaluated and restricted the articles only to the focus of the question in this review. Methodology, the results obtained, and the importance of these results were important to list the selected manuscripts. The selected articles on the topic were carefully read. In addition, two independent reviewers participated in the selection phases, ensuring that the inclusion and exclusion criteria were carefully followed, with the clear objective of minimizing bias.
Data related to the subject of this review were selected and extracted from the manuscripts by independent reviewers, taking into account the characteristics of the individual studies that contributed to their outcome as well as their aggregated results, without the objective of performing a meta-analysis.
The selection scheme, according to the PRISMA flow diagram [,,], is shown in Figure 1.
Figure 1. Flow diagram showing study selection.

3. Results

The bibliography search found 44 articles in the PubMed/MEDLINE database, of which 26 were excluded since they were duplicates or due to inclusion/exclusion criteria. We also found 40 articles in Web of Science and selected 1 article, 152 articles in Scopus and no article selected, totaling 19 articles for qualitative analysis.
From the studies selected for a detailed description, we can see that, due to their physicochemical characteristics, fibrin compounds are widely used in several areas that mainly involve medicine and regenerative dentistry. In this way, three selected studies were selected in which the researchers used hydrogels or 3D fibrin, 3 with L-PRF, 10 with fibrin sealants (or also called glue, adhesive or biopolymers) and 3 with autologous PRF (Figure 2).
Figure 2. Configurations of fibrin preparations used in tissue regenerative processes. Three studies were used hydrogels or 3D fibrin, 3 with L-PRF, 10 with fibrin sealants (or also called glue, adhesive or biopolymers), and 3 with autologous PRF.
Regarding the results of photobiomodulation, we found (according to the eligibility criteria) three studies that used the red LED (Light Emitting Diode - original apparatus LDM-07 or Repuls Lichtmedizintechnik GmbH, Vienna, Austria), 1 infrared LED (original apparatus LDM-07), 1 GaAs (Gallium-Arsenide) laser (Fisioline; Lumix® C.P.S. Dental Multidiodic laser, Verduno, Cuneo, Italy), 10 GaAlAs (Gallium-Aluminum-Arsenide) laser (Laserpulse IBRAMED®, Amparo, Brazil), 2 ND: YAG (neodymium-doped: yttrium aluminium garnet) laser (Fotona, Ljubljana, Slovenia), 1 InGaAlP (Indium-Gallium-Aluminum-Phosphide) laser (MMOptics®, São Carlos, Brazil) and two studies did not identify the type of laser used (Figure 3).
Figure 3. Type of photobiomodulation presented by the selected and evaluated studies. Gallium-Aluminum-Arsenide (GaAlAs) laser that presented greater use in the selected studies in tissue regenerative processes (10 studies). Two studies did not specify the type of PBM used. One study used different types of PBM, therefore considered separately in the data in the figure.
In the photobiomodulation protocols of the selected studies, when the wavelengths were analyzed, the most used was 830 nm, in nine studies. Then, 810 nm in three studies; 475 nm, 516 nm, 635 nm, and 1064 nm in two studies each; 633 nm, 650 nm, 660 nm, 840 nm, 910 nm with one study each; and one study did not disclose the wavelength used (Figure 4).
Figure 4. Protocols of PBM. Wavelength (nm) used by the studies included in Table 1. 830 nm that presented greater use in the selected studies in tissue regenerative processes (nine studies). One study did not present the wavelength used. Studies that used different wavelengths were considered separately in the data in the figure.
The articles selected to compose this review are presented in Table 1.
Table 1. Articles that were selected for detailed analysis, following the eligibility criteria.

4. Discussion

This systematic review aimed to analyze published research on the association of photobiomodulation therapy, through the use of LLLT or LED, with fibrin scaffolds. The focus was on its use in tissue regeneration, mainly fibrin in the form of PRF and fibrin sealants (glues or adhesives) in order to verify the possible beneficial effects of PBM in three-dimensional fibrin scaffolds.
The initial description of fibrin comes from the classic coagulation cascade, proposed in 1964 by Macfarlane [] and Davie and Ratnoff [], documented in several articles. This model referred to as the “cascade” has been proposed to explain the physiology of blood clotting, whereby clotting occurs through sequential proteolytic activation of proenzymes by plasma proteases, resulting in the formation of thrombin, which then breaks down the fibrinogen molecule into fibrin monomers []. The fibrin network formed in the clot presents a particularly homogeneous and three-dimensional organization []. Furthermore, a progressive polymerization mode means increased incorporation of circulating cytokines in the fibrin meshes (intrinsic cytokines), providing an increase in the lifespan of these cytokines. Thus, cytokines are kept in situ for a convenient period when the scar cells begin to remodel the matrix, at which time they need to be stimulated to participate in the reconstruction of the injured site [,].
Due to its characteristics and properties, fibrin has been used in several areas, one of which is tissue regeneration in medical and dental procedures. Among the forms presented, in this review, three studies were selected for qualitative analysis that used hydrogels or 3D fibrin, 3 with L-PRF, 10 with fibrin sealants and 3 with autologous PRF (Figure 2). The production of autologous platelet concentrates (APCs) occurs by centrifuging the patient’s own blood, injecting isolated plasma, which is rich in growth factors. In tissue regeneration, two generations of APCs have been used: PRP, which are first generation, produced by double-spin centrifugation of blood; and PRF, the second generation, produced by single-spin centrifugation and has the fibrin matrix network intact. The effectiveness of platelet concentrates in promoting wound healing and tissue regeneration is at the center of recent academic discussion [].
In a preclinical study, using LLT, PRF and Nano-HA nanohydroxyapatite graft (Fisiograft®, Ghimas, Italy) as variables, Hemaid et al., (2019) observed that the use of PRF + NanoHA mix results in an increase in bone fill and density regarding the radiographic outcomes in induced periodontal intrabony defects in rabbits, and LLLT may improve the results []. To prepare the PRF, five-milliliter blood samples were collected from each rabbit and then centrifuged at 30,000× g RPM for 15 min. The PRF was separated into two pieces; one was used as a membrane and the other was cut into pieces to be added with Fisiograft® plus Nano-HA.
However, the study by Doan et al., (2020) the clinical applicability of the combination of autologous concentrated growth factors (CGF) and photobiomodulation (PBM) was made. Lateral sinus windows were created using piezoelectric surgery (PES) and the dental implants were concurrently fixated and wrapped with autologous fibrin (AF) rich CGF. Wound sites PBM treatment using a multiwave locked system laser. Bovine demineralized freeze-dried bone (Bio-Oss®, Chatswood, Australia) and hydroxyapatite and calcium triphosphate (Genoss®, Seoul, Korea) were incorporated into CGF for grafting. The application of AF offers benefits such as being a safe procedure, easy to perform and low cost [] (Figure 5).
Figure 5. Schematic overview of fibrin applications in tissue regeneration. Fibrin is a plasma protein formed by the action of thrombin on fibrinogen, and constitutes a natural component of the blood coagulation cascade. The three-dimensional structure of the fibrin matrix serves as a natural scaffold that favors cell adhesion, migration, proliferation and differentiation, in addition to favoring the interaction with biomolecules and growth factors. Thus, fibrin has been used to promote tissue regeneration in various segments of medicine, in the form of sealants, hydrogels, PRF or L-PRF.
Three studies used L-PRF, developed in 2001 in France by Dr. Joseph Choukroun [], during the production technique an attempt was made to accumulate platelets and release cytokines in a fibrin clot. This technique does not require anticoagulants, bovine thrombin or any other gelling agent, unlike other platelet concentrates; it is simply centrifuged natural blood without additives [,]. When using L-PRF, there are different methods and protocols in its production. In a pre-clinical study, in critical defects in the calvaria of rats, two methods of obtaining the concentrate were analyzed, by means of high (L-PRF) or low speed (A-PRF) centrifugation. The L-PRF and A-PRF groups had significantly higher bone volume and newly formed bone area than the control group (clot only) and reduced bone porosity values, but with no significant difference between them in the histomorphometric and microtomographic analysis. Therefore, L-PRF and A-PRF potentiated the healing of critical defects, and high and low-speed centrifugation protocols did not produce PRF matrices with different biological impacts on the amount of new bone formation [].
Leukocyte and platelet-rich fibrin (L-PRF) also have been used widely for bone tissue engineering. L-PRF has the potential to, in cases of bone loss, collaborate in osteogenic differentiation, increase osteoblast proliferation, tissue neovascularization and lower risk of local contamination [,]. The three studies in Table 1 that used L-PRF were combinations with PBM for the treatment of jaw osteonecrosis, all with good and promising results for use in the treatment of this type of bone disease [,,]. Among the growth factors stored in platelets, which are essential for the tissue repair, are PDGF. Also present are VEGF-A, transforming growth factor-beta (TGF-β1), FGF–2, epidermal growth factor (EGF), hepatocyte growth factor (HGF), and insulin-like growth factor–1 (IGF–1) []. It should be taken into account the fact that L-PRF does not use the inclusion of anticoagulant and activating agents (CaCl2) to obtain the platelet concentrate. The inclusion of these agents and activators, in addition to hard-centrifugation (≥210 g), can affect the amount and quality of platelet recovery and growth factor release, which can significantly influence healing behavior compared to natural fibrin clotting [].
Three studies were used hydrogels or 3D fibrin [,,], associated with PBM, being incorporated into the fibrin matrix endothelial cells [], stromal vascular fraction (SVF) and mesenchymal stromal cells (MSCs) isolated from human gingival mucosa []. These studies agree that photobiomodulation combined with fibrin enhances the improvement of results, collaborating in cell and vascular proliferation.
Fibrin sealants were most commonly used in combination with PBM, in ten studies [,,,,,,,,,]. One of the studies used the fibrin sealant derived from human plasma (Tisseel Lyo® (Baxter Healthcare Ltd., Norfolk, UK) [] and the others a heterologous fibrin sealant (HFS). This bioproduct (HFS) is composed of a thrombin-like enzyme purified from the venom of Crotalus durissus terrificus snake and a cryoprecipitate rich in fibrinogen extracted from Bubalus bubalis buffaloes (produced by CEVAP/UNESP—Center for the Study of Venoms and Venomous Animals, Botucatu, Brazil). HFS has several advantages in its use, such as a fast production process, low cost, potential to act as a scaffold for stem cells [,,] and biomaterials [,], and as a new drug delivery system []. Its indications are in medical, veterinary and dental practice, due to the possibility of personalized formulation and replacement of conventional sutures. Considering all of the properties described for this bioproduct, which go beyond the adhesive capacity, the name “sealant” was reconsidered, and it has recently been called “fibrin biopolymer” [,].
In order to improve the tissue repair process, studies in the area of regenerative science seek the association of different therapies to accelerate and improve morphological recomposition and faster functional recovery. Among these conjunctions, light-based therapies, such as the use of low-power lasers and LEDs, have expanded their use in clinical and pre-clinical practices. The laser consists of a pure and well-defined color, while the LED can display different shades of colors at once. Therefore, the laser is a monochromatic light (only a well-determined color) and the LED is a polychromatic light, being able to present all of the shades of a specific color. Currently called photobiomodulation (PBM), consists of the application of light (Laser or LED) with therapeutic effect for tissue modulation (activation or inhibition). It has important potentialities such as angiogenesis and neovascularization [], increase in collagen production [], increase in muscle regeneration and decrease in its atrophy [], favors nerve regeneration [,], increases cartilage production [], and decreases inflammation, edema and pain [] (Figure 6).
Figure 6. Schematic overview of beneficial properties of photobiomodulation therapy in regenerative medicine. The application of laser therapy favors angiogenesis, collagen synthesis, mitochondrial ATP production, cytokines and growth factors synthesis, in addition to inducing cell proliferation and differentiation. Additionally, photobiomodulation therapy has anti-inflammatory, analgesic and biostimulating effects, acting mainly in the initial stages of tissue healing.
In the studies selected for Table 1, according to the eligibility criteria, three used the red LED, 1 infrared LED, 1 GaAs laser, 10 GaAlAs laser, 2 ND: YAG laser, 1 InGaAlP laser and two studies did not identify the type of laser used (Figure 3). Handler et al. (2021) carried out a study to investigate the effects of photobiomodulation at wavelengths of 660 nm (Aluminium-gallium-indium-phosphide laser, AlGaInP) and 830 nm (Arsenide-Gallium-Aluminum laser, AsGaAl) at different numbers of application points on the healing of open wounds in mice. Photobiomodulation with total energy of 3.6 J was applied at 1, 4, 5 and 9 points for 14 days. When comparing the photobiomodulation wavelength, the 830 nm (AsGaAl) groups were more effective, and the groups irradiated at 5 points stand out, which showed improvement in macroscopic analysis and epidermis thickness, increased number of vessels and lower number of fibroblasts on the 14th day after the skin lesion [].
Regarding the wavelength, the most used was 830 nm, in nine studies. Then 810 nm in three studies; 475 nm, 516 nm, 635 nm, and 1064 nm in two studies each; 633 nm, 650 nm, 660 nm, 840 nm, and 910 nm with one study each; and one study did not disclose the wavelength used (Figure 4). A study conducted by Ma et al. (2018), to determine the effect of low-level laser therapy (LLLT) on diabetic wound healing and confirm its effect on the activity of healthy human fibroblasts, used PBM with an 830 nm (IR) wavelength, 635 nm (Red) and 635 nm + 830 nm (FX) with the same fluency of 60 J/cm2. Irradiation in the FX and IR groups showed a significant increase in fibroblast proliferation and collagen synthesis compared to the control and RED groups. However, there was no significant difference in collagen synthesis and fibroblast proliferation between the FX group and the IR group. These data allowed the authors to conclude that healthy human fibroblasts showed better cell proliferation and collagen synthesis when irradiated at the wavelength of 635 nm + 830 nm or 830 nm [].
The use of LED photobiomodulation is more recent than laser therapy. Current research advances in the evaluation of the separate or combined use of the two therapies in tissue repair. Doses ranging from 0.1 to 10 J/cm2 and wavelengths from 405 to 1000 nm promote therapeutic benefits in tissue regeneration. Ranges of light energy sources, from lasers to LEDs, have been used and have specific advantages and limitations. There is no consensus on standardized treatment parameters such as wavelengths, therapeutic outcomes and doses, which limits direct comparison and clinical protocol recommendation [,,,,,,].
The use of combined therapies that involve the use of fibrin associated with photobiomodulation therapy has shown to be a promising strategy to favor the regeneration of injured tissues with better quality and less time. When fibrin is applied to the lesion site, it forms a bioactive matrix in the microenvironment that exerts a hemostatic effect, in addition to favoring interactions between cells and biomolecules (Figure 7). These effects, added to those of PBM, constitute a supporting therapy that acts by stimulating cell activity, angiogenesis, and the synthesis of collagen and biomolecules [,,,,,,,,,,].
Figure 7. The application of fibrin combined with photobiomodulation therapy constitutes a promising strategy to favor regeneration in tissue engineering. Fibrin applied to the injury site forms a bioactive matrix that exerts a hemostatic effect, in addition to favoring interactions between cells and biomolecules. Photobiomodulation constitutes a coadjuvant therapy that acts by stimulating cell activity, angiogenesis and the synthesis of collagen and biomolecules. Thus, the application of fibrin associated with photobiomodulation therapy may have a beneficial effect, accelerating tissue healing.
In this review, among preclinical studies, the most researched association of fibrin and photobiomodulation was the use of fibrin sealants in bone or nerve injuries. In clinical studies, the association of PBM with medication-related treatments osteonecrosis of the jaw (MRONJ). All experimental protocols concluded that the association is effective; promoting a more effective repair of lesions, in a shorter period of time and with effectiveness that can reinforce the indication of its use. In peripheral nerves, PBM therapy accelerated morphological and functional nerve repair. In bone tissue [], PBM allowed for an improvement in the formation of new bone, with a more organized deposition of collagen fibers in the defect area []; and in osteonecrosis of the jaw, PBM may effectively contribute to MRONJ management [,,].
In this way, we can see that few studies used the association fibrin + PBM, but given the good results, the technique is promising, with the potential to collaborate in tissue repair. The difficulty in comparing the different types of PBM can be considered as a limitation, due to the different protocols reported in the experiments. Therefore, protocols with favorable results are generally standardized and reused by the same researchers in an attempt to reduce this limitation. In addition, the scarcity of randomized clinical trials in the scope of this review can also be considered a limitation.

5. Conclusions

This review was designed and carried out with the objective of analyzing studies, both clinical and pre-clinical, that used the association of photobiomodulation and fibrin. This association occurs with the purpose of tissue regeneration, in the search for its possible beneficial effects on morphophysiological and functional rehabilitation. The fibrin matrix, with its three-dimensionality, is a natural scaffold, which enables events that favor the repair of injured tissues, which is desired in tissue engineering procedures, through adhesion, migration, proliferation, and cell differentiation, in addition to contributing to the interaction with biomolecules and local tissue growth factors.
In the findings of this study, it can be shown that PBM contributed to improve tissue regeneration that used fibrin composites as scaffolds, constituting an important adjuvant therapy that acts by stimulating cell activity, angiogenesis, osteoblastic activation, axonal growth, anti-inflammatory and anti-edema action, increased collagen synthesis and its maturation, as well as biomolecules. More studies should be carried out in order to seek standardization in PBM protocols, in the same way that new fibrin concentrates will be developed with the same objective of recovering injured organs and tissues.

Author Contributions

Conceptualization, C.H.B.R., D.V.B. and R.L.B.; methodology, A.d.C.O. and S.O.M.F.; software, D.d.B.T.; validation, J.A.D.; formal analysis, M.R.d.C.; investigation, C.H.B.R. and R.L.B.; resources, M.A.M.; data curation, D.d.B.T. and M.R.d.C.; writing—original draft preparation, C.H.B.R., R.L.B. and D.V.B.; writing—review and editing, C.H.B.R. and R.L.B.; visualization, E.d.S.B.M.P.; supervision, R.L.B.; project administration, R.L.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Vilar, R.; Fish, R.J.; Casini, A.; Neerman-Arbez, M. Fibrin(ogen) in human disease: Both friend and foe. Haematologica 2020, 105, 284–296. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Jahani-Sherafat, S.; Mokmeli, S.; Rostami-Nejad, M.; Razzaghi, Z.; Tavirani, M.R.; Razzaghi, M. The Effectiveness of Photobiomudulation Therapy (Pbmt) in COVID-19 Infection. J. Lasers Med. Sci. 2020, 11, S23–S29. [Google Scholar] [CrossRef] [PubMed]
  3. Litvinov, R.I.; Pieters, M.; de Lange-Loots, Z.; Weisel, J.W. Fibrinogen and Fibrin. In Macromolecular Protein Complexes III: Structure and Function. Subcellular Biochemistry; Springer: Berlin/Heidelberg, Germany, 2021; pp. 471–501. [Google Scholar]
  4. Reddy, M.S.B.; Ponnamma, D.; Choudhary, R.; Sadasivuni, K.K. A comparative review of natural and synthetic biopolymer composite scaffolds. Polymers 2021, 13, 1105. [Google Scholar] [CrossRef] [PubMed]
  5. Wang, M.; Gao, W. Fixation of platelet-rich plasma and fibrin gels on knee cartilage defects after microfracture with arthroscopy. Int. Orthop. 2022, 474. [Google Scholar] [CrossRef]
  6. Grecu, A.F.; Reclaru, L.; Ardelean, L.C.; Nica, O.; Ciucă, E.M.; Ciurea, M.E. Platelet-rich fibrin and its emerging therapeutic benefits for musculoskeletal injury treatment. Medicine 2019, 55, 141. [Google Scholar] [CrossRef] [Green Version]
  7. Vasilikos, I.; Beck, J.; Ghanaati, S.; Grauvogel, J.; Nisyrios, T.; Grapatsas, K.; Hubbe, U. Integrity of dural closure after autologous platelet rich fibrin augmentation: An in vitro study. Acta Neurochir. 2020, 162, 737–743. [Google Scholar] [CrossRef] [PubMed]
  8. Buchaim, D.V.; Cassaro, C.V.; Shindo, J.V.T.C.; Coletta, B.B.D.; Pomini, K.T.; De Oliveira Rosso, M.P.; Campos, L.M.G.; Ferreira, R.S.; Barraviera, B.; Buchaim, R.L. Unique heterologous fibrin biopolymer with hemostatic, adhesive, sealant, scaffold and drug delivery properties: A systematic review. J. Venom. Anim. Toxins Incl. Trop. Dis. 2019, 25, 1–15. [Google Scholar] [CrossRef]
  9. Rosso, M.P.d.O.; Buchaim, D.V.; Kawano, N.; Furlanette, G.; Pomini, K.T.; Buchaim, R.L. Photobiomodulation therapy (PBMT) in peripheral nerve regeneration: A systematic review. Bioengineering 2018, 5, 44. [Google Scholar] [CrossRef] [Green Version]
  10. Gentile, P.; Calabrese, C.; De Angelis, B.; Dionisi, L.; Pizzicannella, J.; Kothari, A.; De Fazio, D.; Garcovich, S. Impact of the different preparation methods to obtain autologous non-activated platelet-rich plasma (A-PRP) and activated platelet-rich plasma (AA-PRP) in plastic surgery: Wound healing and hair regrowth evaluation. Int. J. Mol. Sci. 2020, 21, 431. [Google Scholar] [CrossRef] [Green Version]
  11. Bressan, E.; Favero, V.; Gardin, C.; Ferroni, L.; Iacobellis, L.; Favero, L.; Vindigni, V.; Berengo, M.; Sivolella, S.; Zavan, B. Biopolymers for Hard and Soft Engineered Tissues: Application in Odontoiatric and Plastic Surgery Field. Polymers 2011, 3, 509–526. [Google Scholar] [CrossRef]
  12. Pepelassi, E.; Deligianni, M. The Adjunctive Use of Leucocyte-and Platelet-Rich Fibrin in Periodontal Endosseous and Furcation Defects: A Systematic Review and Meta-Analysis. Materials 2022, 15, 2088. [Google Scholar] [CrossRef] [PubMed]
  13. Caramês, J.M.M.; Vieira, F.A.; Caramês, G.B.; Pinto, A.C.; Francisco, H.C.O.; Marques, D.N.D.S. Guided Bone Regeneration in the Edentulous Atrophic Maxilla Using Deproteinized Bovine Bone Mineral (DBBM) Combined with Platelet-Rich Fibrin (PRF)—A Prospective Study. J. Clin. Med. 2022, 11, 894. [Google Scholar] [CrossRef] [PubMed]
  14. Jung, M.H.; Lee, J.H.; Wadhwa, P.; Jiang, H.B.; Jang, H.S.; Lee, E.S. Bone regeneration in peri-implant defect using autogenous tooth biomaterial enriched with platelet-rich fibrin in animal model. Appl. Sci. 2020, 10, 1939. [Google Scholar] [CrossRef] [Green Version]
  15. Tallarico, M.; Xhanari, E.; Lumbau, A.M.I.; Alushi, A.; Ieria, I.; Fiorillo, L.; Famà, F.; Meto, A.; Baldoni, E.; Meloni, S.M.; et al. Histological and histomorphometric evaluation of post-extractive sites filled with a new bone substitute with or without autologous plate concentrates: One-year randomized controlled trial. Materials 2022, 15, 254. [Google Scholar] [CrossRef]
  16. Li, Q.; Reed, D.A.; Min, L.; Gopinathan, G.; Li, S.; Dangaria, S.J.; Li, L.; Geng, Y.; Galang, M.T.; Gajendrareddy, P.; et al. Lyophilized Platelet-Rich Fibrin (PRF) promotes craniofacial bone regeneration through Runx2. Int. J. Mol. Sci. 2014, 15, 8509–8525. [Google Scholar] [CrossRef]
  17. Zumarán, C.C.; Parra, M.V.; Olate, S.A.; Fernández, E.G.; Muñoz, F.T.; Haidar, Z.S. The 3 R’s for platelet-rich fibrin: A “super” tri-dimensional biomaterial for contemporary naturally-guided oro-maxillo-facial soft and hard tissue repair, reconstruction and regeneration. Materials 2018, 11, 1239. [Google Scholar] [CrossRef] [Green Version]
  18. Almeida Barros Mourão, C.F.D.; Valiense, H.; Melo, E.R.; Freitas Mourão, N.B.M.; Maia, M.D.C. Obtenção da fibrina rica em plaquetas injetável (I-PRF) e sua polimerização com enxerto ósseo: Nota técnica. Rev. Col. Bras. Cir. 2015, 42, 421–423. [Google Scholar] [CrossRef] [Green Version]
  19. Pietruszka, P.; Chruścicka, I.; Duś-Ilnicka, I.; Paradowska-Stolarz, A. Prp and prf—Subgroups and divisions when used in dentistry. J. Pers. Med. 2021, 11, 944. [Google Scholar] [CrossRef] [PubMed]
  20. Ikumi, A.; Gingery, A.; Toyoshima, Y.; Zhao, C.; Moran, S.L.; Livia, C.; Rolland, T.; Peterson, T.; Sabbah, M.S.; Boroumand, S.; et al. Administration of Purified Exosome Product in a Rat Sciatic Serve Reverse Autograft Model. Plast. Reconstr. Surg. 2021, 148, 200e–211e. [Google Scholar] [CrossRef]
  21. Ardjomandi, N.; Duttenhoefer, F.; Xavier, S.; Oshima, T.; Kuenz, A.; Sauerbier, S. In vivo comparison of hard tissue regeneration with ovine mesenchymal stem cells processed with either the FICOLL method or the BMAC method. J. Craniomaxillofac. Surg. 2015, 43, 1177–1183. [Google Scholar] [CrossRef]
  22. Mittermayr, R.; Branski, L.; Moritz, M.; Jeschke, M.G.; Herndon, D.N.; Traber, D.; Schense, J.; Gampfer, J.; Goppelt, A.; Redl, H. Fibrin biomatrix-conjugated platelet-derived growth factor AB accelerates wound healing in severe thermal injury. J. Tissue Eng. Regen. Med. 2016, 10, E275–E285. [Google Scholar] [CrossRef]
  23. Hidd, S.M.C.M.; Tim, C.R.; Dutra, E.F., Jr.; Maia Filho, A.L.M.; Assis, L.; Ferreira, R.S., Jr.; Barraviera, B.; Silva, J.F.; Amaral, M.M. Fibrin biopolymer sealant and aquatic exercise association for calcaneal tendon repair. Acta Cir. Bras. 2021, 36, e360407. [Google Scholar] [CrossRef]
  24. Canonico, S. The use of human fibrin glue in the surgical operations. Acta Biomed. 2003, 74, 21–25. [Google Scholar]
  25. Su, Y.Y.; Lin, Y.S.; Yang, L.Y.; Pan, Y.B.; Huang, Y.T.; Weng, C.H.; Wu, K.Y.; Wang, C.J. Use of human fibrin glue (Tisseel) versus suture during transvaginal natural orifice ovarian cystectomy of benign and non-endometriotic ovarian tumor: A retrospective comparative study. BMC Surg. 2021, 21, 1–8. [Google Scholar] [CrossRef]
  26. Ferreira, R.S.; de Barros, L.C.; Abbade, L.P.F.; Barraviera, S.R.C.S.; Silvares, M.R.C.; de Pontes, L.G.; dos Santos, L.D.; Barraviera, B. Heterologous fibrin sealant derived from snake venom: From bench to bedside—An overview. J. Venom. Anim. Toxins Incl. Trop. Dis. 2017, 23, 1–12. [Google Scholar] [CrossRef] [Green Version]
  27. Anders, J.J.; Lanzafame, R.J.; Arany, P.R. Low-level light/laser therapy versus photobiomodulation therapy. Photomed. Laser Surg. 2015, 33, 183–184. [Google Scholar] [CrossRef] [Green Version]
  28. Hamblin, M.R. Photobiomodulation or low-level laser therapy. J. Biophotonics 2016, 9, 1122–1124. [Google Scholar] [CrossRef]
  29. Buchaim, R.L.; Andreo, J.C.; Barraviera, B.; Ferreira Junior, R.S.; Buchaim, D.V.; Rosa Junior, G.M.; De Oliveira, A.L.R.; De Castro Rodrigues, A. Effect of low-level laser therapy (LLLT) on peripheral nerve regeneration using fibrin glue derived from snake venom. Injury 2015, 46, 655–660. [Google Scholar] [CrossRef]
  30. Iatecola, A.; Barraviera, B.; Ferreira, R.S., Jr.; dos Santos, G.R.; Neves, J.I.; da Cunha, M.R. Use of a new fibrin sealant and laser irradiation in the repair of skull defects in rats. Braz. Dent. J. 2013, 24, 456–461. [Google Scholar] [CrossRef]
  31. Santos, C.M.D.C.; Pimenta, C.A.D.M.; Nobre, M.R.C. The PICO strategy for the research question construction and evidence search. Rev. Lat. Am. Enfermagem 2007, 15, 508–511. [Google Scholar] [CrossRef] [Green Version]
  32. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Altman, D.; Antes, G.; Atkins, D.; Barbour, V.; Barrowman, N.; Berlin, J.A.; et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009, 6, e1000097. [Google Scholar] [CrossRef] [Green Version]
  33. Gentile, P.; Garcovich, S. Systematic review—The potential implications of different platelet-rich plasma (Prp) concentrations in regenerative medicine for tissue repair. Int. J. Mol. Sci. 2020, 21, 5702. [Google Scholar] [CrossRef]
  34. Rosso, M.P.D.O.; Buchaim, D.V.; Pomini, K.T.; Coletta, B.B.D.; Reis, C.H.B.; Pilon, J.P.G.; Júnior, G.D.; Buchaim, R.L. Photobiomodulation therapy (PBMT) applied in bone reconstructive surgery using bovine bone grafts: A systematic review. Materials 2019, 12, 4051. [Google Scholar] [CrossRef] [Green Version]
  35. Ortiz, A.d.C.; Fideles, S.O.M.; Pomini, K.T.; Bellini, M.Z.; Pereira, E.S.B.M.; Reis, C.H.B.; Pilon, J.P.G.; de Marchi, M.Â.; Trazzi, B.F.d.M.; da Silva, W.S.; et al. Potential of Fibrin Glue and Mesenchymal Stem Cells (MSCs) to Regenerate Nerve Injuries: A Systematic Review. Cells 2022, 11, 221. [Google Scholar] [CrossRef]
  36. Ortiz, A.d.C.; Fideles, S.O.M.; Pomini, K.T.; Reis, C.H.B.; Bueno, C.R.d.S.; Pereira, E.d.S.B.M.; Rossi, J.d.O.; Novais, P.C.; Pilon, J.P.G.; Rosa Junior, G.M.; et al. Effects of Therapy with Fibrin Glue combined with Mesenchymal Stem Cells (MSCs) on Bone Regeneration: A Systematic Review. Cells 2021, 10, 2323. [Google Scholar] [CrossRef]
  37. Bikmulina, P.Y.; Kosheleva, N.V.; Shpichka, A.I.; Efremov, Y.M.; Yusupov, V.I.; Timashev, P.S.; Rochev, Y.A. Beyond 2D: Effects of photobiomodulation in 3D tissue-like systems. J. Biomed. Opt. 2020, 25, 048001. [Google Scholar] [CrossRef]
  38. Tenore, G.; Zimbalatti, A.; Rocchetti, F.; Graniero, F.; Gaglioti, D.; Mohsen, A.; Caputo, M.; Lollobrigida, M.; Lamazza, L.; De Biase, A.; et al. Management of medication-related osteonecrosis of the jaw (MRONJ) using leukocyte-and platelet-rich fibrin (l-PRF) and photobiomodulation: A retrospective study. J. Clin. Med. 2020, 9, 3505. [Google Scholar] [CrossRef]
  39. de Oliveira Gonçalves, J.B.; Buchaim, D.V.; de Souza Bueno, C.R.; Pomini, K.T.; Barraviera, B.; Júnior, R.S.F.; Andreo, J.C.; de Castro Rodrigues, A.; Cestari, T.M.; Buchaim, R.L. Effects of low-level laser therapy on autogenous bone graft stabilized with a new heterologous fibrin sealant. J. Photochem. Photobiol. B Biol. 2016, 162, 663–668. [Google Scholar] [CrossRef] [Green Version]
  40. Buchaim, D.V.; Andreo, J.C.; Ferreira Junior, R.S.; Barraviera, B.; De Castro Rodrigues, A.; De Cássia MacEdo, M.; Rosa Junior, G.M.; Shinohara, A.L.; German, I.J.S.; Pomini, K.T.; et al. Efficacy of Laser Photobiomodulation on Morphological and Functional Repair of the Facial Nerve. Photomed. Laser Surg. 2017, 35, 442–449. [Google Scholar] [CrossRef]
  41. Rohringer, S.; Holnthoner, W.; Chaudary, S.; Slezak, P.; Priglinger, E.; Strassl, M.; Pill, K.; Mühleder, S.; Redl, H.; Dungel, P. The impact of wavelengths of LED light-therapy on endothelial cells. Sci. Rep. 2017, 7, 11061. [Google Scholar] [CrossRef]
  42. Priglinger, E.; Maier, J.; Chaudary, S.; Lindner, C.; Wurzer, C.; Rieger, S.; Redl, H.; Wolbank, S.; Dungel, P. Photobiomodulation of freshly isolated human adipose tissue-derived stromal vascular fraction cells by pulsed light-emitting diodes for direct clinical application. J. Tissue Eng. Regen. Med. 2018, 12, 1352–1362. [Google Scholar] [CrossRef]
  43. Pomini, K.T.; Buchaim, D.V.; Andreo, J.C.; Rosso, M.P.; Della Coletta, B.B.; German, Í.J.S.; Biguetti, A.C.C.; Shinohara, A.L.; Rosa Júnior, G.M.; Shindo, J.V.T.C.; et al. Fibrin sealant derived from human plasma as a scaffold for bone grafts associated with photobiomodulation therapy. Int. J. Mol. Sci. 2019, 20, 1761. [Google Scholar] [CrossRef] [Green Version]
  44. Hemaid, S.; Saafan, A.; Hosny, M.; Wimmer, G. Enhancement of healing of periodontal intrabony defects using 810 nm diode laser and different advanced treatment modalities: A blind experimental study. Open Access Maced. J. Med. Sci. 2019, 7, 1847–1853. [Google Scholar] [CrossRef] [Green Version]
  45. Şahin, O.; Tatar, B.; Ekmekcioğlu, C.; Aliyev, T.; Odabaşi, O. Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery: An institution’s experience. J. Clin. Exp. Dent. 2020, 12, e771–e776. [Google Scholar] [CrossRef]
  46. Thalaimalai, D.B.R.; Victor, D.J.; Prakash, P.S.G.; Subramaniam, S.; Cholan, P.K. Effect of Low-Level Laser Therapy and Platelet-Rich Fibrin on the Treatment of Intra-bony Defects. J. Lasers Med. Sci. 2020, 11, 456–463. [Google Scholar] [CrossRef]
  47. Della Coletta, B.B.; Jacob, T.B.; Moreira, L.A.d.C.; Pomini, K.T.; Buchaim, D.V.; Eleutério, R.G.; Pereira, E.d.S.B.M.; Roque, D.D.; Rosso, M.P.d.O.; Shindo, J.V.T.C.; et al. Photobiomodulation Therapy on the Guided Bone Regeneration Process in Defects Filled by Biphasic Calcium Phosphate Associated with Fibrin Biopolymer. Molecules 2021, 26, 847. [Google Scholar] [CrossRef]
  48. Şahin, O.; Akan, E.; Tatar, B.; Ekmekcioğlu, C.; Ünal, N.; Odabaşı, O. Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients. Braz. J. Otorhinolaryngol. 2021, 88, 613–620. [Google Scholar] [CrossRef]
  49. de Freitas Dutra Júnior, E.; Hidd, S.M.C.M.; Amaral, M.M.; Filho, A.L.M.M.; Assis, L.; Ferreira, R.S.; Barraviera, B.; Martignago, C.C.S.; Figueredo-Silva, J.; de Oliveira, R.A.; et al. Treatment of partial injury of the calcaneus tendon with heterologous fibrin biopolymer and/or photobiomodulation in rats. Lasers Med. Sci. 2022, 37, 971–981. [Google Scholar] [CrossRef] [PubMed]
  50. Buchaim, D.V.; Andreo, J.C.; Pomini, K.T.; Barraviera, B.; Ferreira, R.S.; Duarte, M.A.H.; Alcalde, M.P.; Reis, C.H.B.; de Bortoli Teixeira, D.; de Souza Bueno, C.R.; et al. A biocomplex to repair experimental critical size defects associated with photobiomodulation therapy. J. Venom. Anim. Toxins Incl. Trop. Dis. 2022, 28, 1–14. [Google Scholar] [CrossRef] [PubMed]
  51. Rosso, M.P.d.O.; Rosa Júnior, G.M.; Buchaim, D.V.; German, I.J.S.; Pomini, K.T.; de Souza, R.G.; Pereira, M.; Favaretto Júnior, I.A.; Bueno, C.R.d.S.; Gonçalves, J.B.d.O.; et al. Stimulation of morphofunctional repair of the facial nerve with photobiomodulation, using the end-to-side technique or a new heterologous fibrin sealant. J. Photochem. Photobiol. B Biol. 2017, 175, 20–28. [Google Scholar] [CrossRef] [Green Version]
  52. de Oliveira Rosso, M.P.; Oyadomari, A.T.; Pomini, K.T.; Coletta, B.B.D.; Shindo, J.V.T.C.; Júnior, R.S.F.; Barraviera, B.; Cassaro, C.V.; Buchaim, D.V.; Teixeira, D.d.B.; et al. Photobiomodulation therapy associated with heterologous fibrin biopolymer and bovine bone matrix helps to reconstruct long bones. Biomolecules 2020, 10, 383. [Google Scholar] [CrossRef] [Green Version]
  53. Buchaim, D.V.; Rodrigues, A.C.; Buchaim, R.L.; Barraviera, B.; Junior, R.S.F.; Junior, G.M.R.; Bueno, C.R.S.; Roque, D.D.; Dias, D.V.; Dare, L.R.; et al. The new heterologous fibrin sealant in combination with low-level laser therapy (LLLT) in the repair of the buccal branch of the facial nerve. Lasers Med. Sci. 2016, 31, 965–972. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Doan, N.V.; Huynh, T.Q.; Tran, S.; Wang, G.; Hamlet, S.; Dau, V.; Dao, D.; Nguyen, N.T.; Nguyen, H.T.; Doan, J.; et al. Multidisciplinary approach to maximize angiogenesis and wound healing using piezoelectric surgery, concentrated growth factors and photobiomodulation for dental implant placement surgery involving lateral wall sinus lift: Two case reports. Vasc. Cell 2020, 12, 2. [Google Scholar] [CrossRef]
  55. Macfarlane, R.G. An Enzyme Cascade in the Blood Clotting Mechanism, and its Function as a Biochemical Amplifier. Nature 1964, 202, 498–499. [Google Scholar] [CrossRef]
  56. Davie, E.W.; Ratnoff, O.D. Waterfall sequence for intrinsec blood clotting. Science 1964, 145, 1310–1312. [Google Scholar] [CrossRef] [PubMed]
  57. Ferreira, C.N.; Sousa, M.O.; Dusse, L.M.S.; Carvalho, M.G. A cell-based model of coagulation and its implications. Rev. Bras. Hematol. Hemoter. 2010, 32, 416–421. [Google Scholar] [CrossRef] [Green Version]
  58. Dohan, D.M.; Choukroun, J.; Diss, A.; Dohan, S.L.; Dohan, A.J.J.; Mouhyi, J.; Gogly, B. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part II: Platelet-related biologic features. Oral Surg. Oral Med. Oral Pathol. Oral Radiol Endodontology 2006, 101, e45–e50. [Google Scholar] [CrossRef] [PubMed]
  59. Van Hinsbergh, V.W.M.; Collen, A.; Koolwijk, P. Role of fibrin matrix in angiogenesis. Ann. N. Y. Acad. Sci. 2001, 936, 426–437. [Google Scholar] [CrossRef] [PubMed]
  60. Rodrigues, G.; Fabris, V.; Mallmann, F.; Rech, C.A.; Carvalho, R.V.; Ruschel, G.H. Fibrinas Ricas em Plaquetas, Uma Alternativa para Regeneração Tecidual: Revisão de Literatura. J. Oral Investig. 2015, 4, 57–62. [Google Scholar] [CrossRef]
  61. Khurshid, Z.; Asiri, F.Y.I.; Najeeb, S.; Ratnayake, J. The Impact of Autologous Platelet Concentrates on the Periapical Tissues and Root Development of Replanted Teeth: A Systematic Review. Materials 2022, 15, 2776. [Google Scholar] [CrossRef]
  62. Choukroun, J.; Adda, F.; Schoeffler, C.; Vervelle, A. An opportunity in perio-implantology: The PRF. Implantodontie 2001, 42, 55–62. [Google Scholar]
  63. Sahu, K.; Jadhav, S.; Khan, S.S.n.; Singh, N.; Khan, M.; Agarwal, A. Choukroun’s platelet-rich fibrin (L-PRF): A benevolence to surgical and reconstructive dentistry. Int. J. Oral Care Res. 2020, 8, 45. [Google Scholar] [CrossRef]
  64. da Silva, L.M.P.; Sávio, D.D.S.F.; de Ávila, F.C.; Vicente, R.M.; Reis, G.G.D.; Denardi, R.J.; da Costa, N.M.M.; Silva, P.H.F.; de Almeida Barros Mourão, C.F.; Miron, R.J.; et al. Comparison of the effects of platelet concentrates produced by high and low-speed centrifugation protocols on the healing of critical-size defects in rat calvaria: A microtomographic and histomorphometric study low-speed centrifugation protocols on the h. Platelets 2022, 1–10. [Google Scholar] [CrossRef]
  65. Maaruf, N.A.; Jusoh, N. Angiogenic and Osteogenic Properties of Fibrin in Bone Tissue Engineering. Mal. J. Med. Health Sci. 2022, 18, 85–94. [Google Scholar]
  66. do Lago, E.S.; Ferreira, S.; Garcia, I.R.; Okamoto, R.; Mariano, R.C. Improvement of bone repair with l-PRF and bovine bone in calvaria of rats. histometric and immunohistochemical study. Clin. Oral Investig. 2020, 24, 1637–1650. [Google Scholar] [CrossRef]
  67. Crisci, A.; Marotta, G.; Licito, A.; Serra, E.; Benincasa, G.; Crisci, M. Use of Leukocyte Platelet (L-PRF) Rich Fibrin in Diabetic Foot Ulcer with Osteomyelitis (Three Clinical Cases Report). Diseases 2018, 6, 30. [Google Scholar] [CrossRef] [Green Version]
  68. Fernández-Medina, T.; Vaquette, C.; Ivanovski, S. Systematic comparison of the effect of four clinical-grade platelet rich hemoderivatives on osteoblast behaviour. Int. J. Mol. Sci. 2019, 20, 6243. [Google Scholar] [CrossRef] [Green Version]
  69. Orsi, P.R.; Landim-Alvarenga, F.C.; Justulin, L.A.; Kaneno, R.; De Assis Golim, M.; Dos Santos, D.C.; Creste, C.F.Z.; Oba, E.; Maia, L.; Barraviera, B.; et al. A unique heterologous fibrin sealant (HFS) as a candidate biological scaffold for mesenchymal stem cells in osteoporotic rats. Stem Cell Res. Ther. 2017, 8, 654. [Google Scholar] [CrossRef] [Green Version]
  70. Cassaro, C.V.; Justulin, L.A.; De Lima, P.R.; De Assis Golim, M.; Biscola, N.P.; De Castro, M.V.; De Oliveira, A.L.R.; Doiche, D.P.; Pereira, E.J.; Ferreira, R.S.; et al. Fibrin biopolymer as scaffold candidate to treat bone defects in rats. J. Venom. Anim. Toxins Incl. Trop. Dis. 2019, 25, 1–17. [Google Scholar] [CrossRef] [Green Version]
  71. Mozafari, R.; Kyrylenko, S.; Castro, M.V.; Ferreira, R.S.; Barraviera, B.; Oliveira, A.L.R. Combination of heterologous fibrin sealant and bioengineered human embryonic stem cells to improve regeneration following autogenous sciatic nerve grafting repair. J. Venom. Anim. Toxins Incl. Trop. Dis. 2018, 24, 1–16. [Google Scholar] [CrossRef] [PubMed]
  72. Reis, C.H.B.; Buchaim, R.L.; Pomini, K.T.; Hamzé, A.L.; Zattiti, I.V.; Duarte, M.A.H.; Alcalde, M.P.; Barraviera, B.; Ferreira Júnior, R.S.; Pontes, F.M.L.; et al. Effects of a Biocomplex Formed by Two Scaffold Biomaterials, Hydroxyapatite/Tricalcium Phosphate Ceramic and Fibrin Biopolymer, with Photobiomodulation, on Bone Repair. Polymers 2022, 14, 2075. [Google Scholar] [CrossRef] [PubMed]
  73. Venante, H.S.; Chappuis-Chocano, A.P.; Marcillo-Toala, O.O.; Da Silva, R.A.; Da Costa, R.M.B.; Pordeus, M.D.; Barraviera, B.; Junior, R.S.F.; Lara, V.S.; Neppelenbroek, K.H.; et al. Fibrin biopolymer incorporated with antimicrobial agents: A proposal for coating denture bases. Materials 2021, 14, 1618. [Google Scholar] [CrossRef] [PubMed]
  74. Buchaim, R.L.; Goissis, G.; Andreo, J.C.; Roque, D.D.; Roque, J.S.; Buchaim, D.V.; Rodrigues, A.d.C. Biocompatibility of anionic collagen matrices and its influence on the orientation of cellular growth. Braz. Dent. Sci. 2007, 10, 12–20. [Google Scholar] [CrossRef]
  75. Buchaim, R.L.; Buchaim, D.V. Laser Therapy Together with a Fibrin Biopolymer Improves Nerve and Bone Tissue Regeneration. SciELO Perspect. 2022. P2022. Available online: https://pressreleases.scielo.org/en/2022/06/06/laser-therapy-together-with-a-fibrin-biopolymer-improves-nerve-and-bone-tissue-regeneration/ (accessed on 12 June 2022).
  76. Simões, T.M.S.; Fernandes Neto, J.d.A.; de Oliveira, T.K.B.; Nonaka, C.F.W.; Catão, M.H.C.d.V. Photobiomodulation of red and green lights in the repair process of third-degree skin burns. Lasers Med. Sci. 2020, 35, 51–61. [Google Scholar] [CrossRef] [PubMed]
  77. Souza, C.; Jayme, C.C.; Rezende, N.; Tedesco, A.C. Synergistic effect of photobiomodulation and phthalocyanine photosensitizer on fibroblast signaling responses in an in vitro three-dimensional microenvironment. J. Photochem. Photobiol. B Biol. 2021, 222, 112256. [Google Scholar] [CrossRef] [PubMed]
  78. Mandelbaum-Livnat, M.M.; Almog, M.; Nissan, M.; Loeb, E.; Shapira, Y.; Rochkind, S. Photobiomodulation triple treatment in peripheral nerve injury: Nerve and muscle response. Photomed. Laser Surg. 2016, 34, 638–645. [Google Scholar] [CrossRef]
  79. Della Santa, G.M.L.; Ferreira, M.C.; Machado, T.P.G.; Oliveira, M.X.; Santos, A.P. Effects of Photobiomodulation Therapy (LED 630 nm) on Muscle and Nerve Histomorphometry after Axonotmesis. Photochem. Photobiol. 2021, 97, 1116–1122. [Google Scholar] [CrossRef]
  80. Tim, C.R.; Martignago, C.C.S.; Assis, L.; Neves, L.M.; Andrade, A.L.; Silva, N.C.; Parizotto, N.; Pinto, K.Z.; Rennó, A.C. Effects of photobiomodulation therapy in chondrocyte response by in vitro experiments and experimental model of osteoarthritis in the knee of rats. Lasers Med. Sci. 2022, 37, 1677–1686. [Google Scholar] [CrossRef]
  81. Gonçalves, A.B.; Bovo, J.L.; Goines, B.S.; Pigoso, A.A.; Felonato, M.; Esquisatto, M.A.M.; de Jesus Lopes Filho, G.; do Bomfim, F.R.C. Photobiomodulation (λ = 808nm) and Platelet-Rich Plasma (PRP) for the Treatment of Acute Rheumatoid Arthritis in Wistar Rats. J. Lasers Med. Sci. 2021, 12, e60. [Google Scholar] [CrossRef]
  82. Hendler, K.G.; Canever, J.B.; de Souza, L.G.; das Neves, L.M.S.; de Cássia Registro Fonseca, M.; Kuriki, H.U.; da Silva Aguiar Junior, A.; Barbosa, R.I.; Marcolino, A.M. Comparison of photobiomodulation in the treatment of skin injury with an open wound in mice. Lasers Med. Sci. 2021, 36, 1845–1854. [Google Scholar] [CrossRef]
  83. Ma, H.; Yang, J.-P.; Tan, R.K.; Lee, H.-W.; Han, S.-K. Effect of Low-Level Laser Therapy on Proliferation and Collagen Synthesis of Human Fibroblasts in Vitro. J. Wound Manag. Res. 2018, 14, 1–6. [Google Scholar] [CrossRef]
  84. Mosca, R.C.; Ong, A.A.; Albasha, O.; Bass, K.; Arany, P. Photobiomodulation Therapy for Wound Care: A Potent, Noninvasive, Photoceutical Approach. Adv. Ski. Wound Care 2019, 32, 157–167. [Google Scholar] [CrossRef]
  85. Escudero, J.S.B.; Perez, M.G.B.; de Oliveira Rosso, M.P.; Buchaim, D.V.; Pomini, K.T.; Campos, L.M.G.; Audi, M.; Buchaim, R.L. Photobiomodulation therapy (PBMT) in bone repair: A systematic review. Injury 2019, 50, 1853–1867. [Google Scholar] [CrossRef] [PubMed]
  86. Nica, D.F.; Riviș, M.; Roi, C.I.; Todea, C.D.; Duma, V.F.; Sinescu, C. Complementarity of photo-biomodulation, surgical treatment, and antibiotherapy for medication-related osteonecrosis of the jaws (Mronj). Medicine 2021, 57, 145. [Google Scholar] [CrossRef] [PubMed]
  87. Mosca, R.C.; Santos, S.N.; Nogueira, G.E.C.; Pereira, D.L.; Costa, F.C.; Pereira, J.X.; Zeituni, C.A.; Arany, P.R. The Efficacy of Photobiomodulation Therapy in Improving Tissue Resilience and Healing of Radiation Skin Damage. Photonics 2022, 9, 10. [Google Scholar] [CrossRef]
  88. Luca, R.E.; Giuliani, A.; Mănescu, A.; Heredea, R.; Hoinoiu, B.; Constantin, G.D.; Duma, V.-F.; Todea, C.D. Osteogenic Potential of Bovine Bone Graft in Combination with Laser Photobiomodulation: An Ex Vivo Demonstrative Study in Wistar Rats by Cross-Linked Studies Based on Synchrotron Microtomography and Histology. Int. J. Mol. Sci. 2020, 21, 778. [Google Scholar] [CrossRef] [Green Version]
  89. Borges, R.M.M.; Cardoso, D.S.; Flores, B.C.; da Luz, R.D.; Machado, C.R.; Cerveira, G.P.; Daitx, R.B.; Dohnert, M.B. Effects of different photobiomodulation dosimetries on temporomandibular dysfunction: A randomized, double-blind, placebo-controlled clinical trial. Lasers Med. Sci. 2018, 33, 1859–1866. [Google Scholar] [CrossRef]
  90. Pinheiro, A.L.; Gerbi, M.E. Photoengineering of bone repair processes. Photomed Laser Surg. 2006, 24, 169–178. [Google Scholar] [CrossRef] [PubMed]
  91. Colombo, E.; Signore, A.; Aicardi, S.; Zekiy, A.; Utyuzh, A.; Benedicenti, S.; Amaroli, A. Experimental and Clinical Applications of Red and Near-Infrared Photobiomodulation on Endothelial Dysfunction: A Review. Biomedicines 2021, 9, 274. [Google Scholar] [CrossRef] [PubMed]
  92. Mendes, C.; Dos Santos Haupenthal, D.P.; Zaccaron, R.P.; de Bem Silveira, G.; Corrêa, M.E.A.B.; de Roch Casagrande, L.; de Sousa Mariano, S.; de Souza Silva, J.I.; de Andrade, T.A.M.; Feuser, P.E.; et al. Effects of the Association between Photobiomodulation and Hyaluronic Acid Linked Gold Nanoparticles in Wound Healing. ACS Biomater. Sci. Eng. 2020, 6, 5132–5144. [Google Scholar] [CrossRef]
  93. Tripodi, N.; Corcoran, D.; Antonello, P.; Balic, N.; Caddy, D.; Knight, A.; Meehan, C.; Sidiroglou, F.; Fraser, S.; Kiatos, D.; et al. The effects of photobiomodulation on human dermal fibroblasts in vitro: A systematic review. J. Photochem. Photobiol. B 2021, 214, 112100. [Google Scholar] [CrossRef]
  94. Cios, A.; Ciepielak, M.; Szymański, Ł.; Lewicka, A.; Cierniak, S.; Stankiewicz, W.; Mendrycka, M.; Lewicki, S. Effect of Different Wavelengths of Laser Irradiation on the Skin Cells. Int. J. Mol. Sci. 2021, 22, 2437. [Google Scholar] [CrossRef]
  95. Ailioaie, L.M.; Litscher, G. Curcumin and Photobiomodulation in Chronic Viral Hepatitis and Hepatocellular Carcinoma. Int. J. Mol. Sci. 2020, 21, 7150. [Google Scholar] [CrossRef] [PubMed]
  96. Kumar Rajendran, N.; George, B.P.; Chandran, R.; Tynga, I.M.; Houreld, N.; Abrahamse, H. The Influence of Light on Reactive Oxygen Species and NF-kB in Disease Progression. Antioxidants 2019, 8, 640. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  97. Spannbauer, A.; Mester-Tonczar, J.; Traxler, D.; Kastner, N.; Zlabinger, K.; Hašimbegović, E.; Riesenhuber, M.; Pavo, N.; Goliasch, G.; Gyöngyösi, M. Large Animal Models of Cell-Free Cardiac Regeneration. Biomolecules 2020, 10, 1392. [Google Scholar] [CrossRef] [PubMed]
  98. Inchingolo, F.; Hazballa, D.; Inchingolo, A.D.; Malcangi, G.; Marinelli, G.; Mancini, A.; Maggiore, M.E.; Bordea, I.R.; Scarano, A.; Farronato, M.; et al. Innovative Concepts and Recent Breakthrough for Engineered Graft and Constructs for Bone Regeneration: A Literature Systematic Review. Materials 2022, 15, 1120. [Google Scholar] [CrossRef] [PubMed]
  99. Chaudary, S.; Karner, L.; Weidinger, A.; Meixner, B.; Rieger, S.; Metzger, M.; Zipperle, J.; Dungel, P. In vitro effects of 635 nm photobiomodulation under hypoxia/reoxygenation culture conditions. J. Photochem. Photobiol. B 2020, 209, 111935. [Google Scholar] [CrossRef]
  100. Dos Santos Ferreira, F.; Cadoná, F.C.; Aurélio, A.R.; de Oliveira Martins, T.N.; Pivetta, H.M.F. Photobiomodulation-blue and red LED: Protection or cellular toxicity? In vitro study with human fibroblasts. Lasers Med. Sci. 2022, 37, 523–530. [Google Scholar] [CrossRef]
  101. Robijns, J.; Censabella, S.; Bulens, P.; Maes, A.; Mebis, J. The use of low-level light therapy in supportive care for patients with breast cancer: Review of the literature. Lasers Med. Sci. 2017, 32, 229–242. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.